The double-edge sword effect of anti-CD73 cancer therapy

Oncoimmunology. 2012 Mar 1;1(2):217-218. doi: 10.4161/onci.1.2.18101.


We and others have identified CD73 as a new cancer target. I hereafter discuss that targeted blockade of CD73 has the effect of a "double-edge sword," able on the one hand to rescue endogenous adaptive anti-tumor immune responses, and on the other hand, inhibit the metastatic potential of tumor cells.